Complex Disease - Cohort Integration Working Group

Our aim is to bring together clinical information and biosamples from 100,000 individuals with Parkinson’s disease (PD) who have donated their time and effort to help us understand and treat the disease.

We are assembling clinical and genetic data from eligible existing cohorts, as well as new cohorts of individuals with PD and healthy controls as part of the global collaboration. We have made great strides in PD research by comparing the genetic makeup of affected people with unaffected controls. This has enabled us to understand risk factor genes.

As part of this study we aim to understand variations between people with PD. For example, why some people progress slowly and some quickly and why some people develop side effects to medication and others have no problems. To understand this, we need to study genetic and clinical data together and we are collaborating with clinical cohorts worldwide to collate and study this data.

Working Group
Huw Morris, FRCP, PhD
Biography
Lead, Complex Disease Cohort Integration

Huw Morris, FRCP, PhD

University College London | United Kingdom
Clodagh Towns, MRes
Biography
Working Group Participant

Clodagh Towns, MRes

University College London | United Kingdom
Hirotaka Iwaki, MD, PhD
Biography
Co-lead, Complex Disease Cohort Integration

Hirotaka Iwaki, MD, PhD

Data Technica International / National Institutes of Health | USA
Manuela Tan, BSc
Biography
Co-lead, Complex Disease Cohort Integration

Manuela Tan, BSc

University College London | United Kingdom
Alejandro Martinez Carrasco, MSc
Biography
PhD Student

Alejandro Martinez Carrasco, MSc

University College London | United Kingdom
Milestones
Progress so far
  • Inclusion of 138 cohorts from 30+ countries
  • 67 cohorts approved and in the process of transferring samples
  • 22 cohorts have had samples genotyped at four genotyping centers
Remaining Year 3 Goals
  • To start clinical data cleaning and analysis

Contact Us

Please contact us if you would like to be involved or have any questions: [email protected]